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Abstract
Background: Delay to start antiretroviral therapy (ART) and nonadherence compromise the health and wellbeing
of people living with HIV (PLWH), raise the cost of care and increase risk of transmission to sexual partners. To date,
interventions to improve adherence to ART have had limited success, perhaps because they have failed to systematically
elicit and address both perceptual and practical barriers to adherence. The primary aim of this study is to determine the
efficacy of the Supporting UPtake and Adherence (SUPA) intervention.
Methods: This study comprises 2 phases. Phase 1 is an observational cohort study, in which PLWH who are ART naïve
and recommended to take ART by their clinician complete a questionnaire assessing their beliefs about ART over 12
months. Phase 2 is a randomised controlled trial (RCT) nested within the observational cohort study to investigate the
effectiveness of the SUPA intervention on adherence to ART. PLWH at risk of nonadherence (based on their beliefs about
ART) will be recruited and randomised 1:1 to the intervention (SUPA intervention + usual care) and control (usual care)
arms. The SUPA intervention involves 4 tailored treatment support sessions delivered by a Research Nurse utilising a
collaborative Cognitive Behavioural Therapy (CBT) and Motivational Interviewing (MI) approach. Sessions are tailored to
individual needs and preferences based on the individual patient’s perceptions and practical barriers to ART. An animation
series and intervention manual have been developed to communicate a rationale for the personal necessity for ART and
illustrate concerns and potential solutions. The primary outcome is adherence to ART measured using Medication Event
Monitoring System (MEMS). Three hundred seventy-two patients will be sufficient to detect a 15% difference in
adherence with 80% power and an alpha of 0.05. Costs will be compared between intervention and control groups.
Costs will be combined with the primary outcome in cost-effectiveness analyses. Quality adjusted life-years (QALYs) will
also be estimated over the follow-up period and used in the analyses.
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Discussion: The findings will enable patients, healthcare providers and policy makers to make informed decisions about
the value of the SUPA intervention.
Trial registration: The trial was retrospectively registered 21/02/2014, ISRCTN35514212.
Keywords: Adherence, Engagement, Antiretroviral therapy, HIV, Randomised controlled trial, Beliefs about medicines,
Perceptions, Cognitive behavioural therapy, Motivational interviewing
Background
Antiretroviral therapy (ART) has resulted in near-normal
life expectancy for many people living with HIV (PLWH)
[1] and there is solid evidence that viral suppression in
PLWH taking ART prevents sexual transmission of HIV
[2]. In the UK, uptake of ART among people with diag-
nosed HIV attending healthcare services is generally high,
but a significant number of PLWH are not on ART [3].
The number of people with diagnosed HIV who are not
taking ART is likely to be an underestimate because not
everyone who is prescribed ART actually receives or takes
it [4]. Furthermore, several studies show that nonadher-
ence to ART remains suboptimal: a meta-analysis of 84
studies across 20 different countries found the mean rate
of ART adherence (defined as ≥90%) was 62% [5]. In a
more recent UK study, 873 (32%) of 2704 people taking
ART reported nonadherence [6]. Delay to start ART and
nonadherence compromise the health and wellbeing of in-
dividual patients, raise the cost of care and impact on pub-
lic health through increased risk of transmission [7, 8].
Adherence to effective treatment should not only improve
physical health, but also psychological wellbeing by
empowering patients to take an active role in managing
their condition [9]. Interventions to increase adherence to
medicines have had limited success and it is not clear
which strategies are most effective. Systematic reviews of
adherence interventions have reported variable findings
[10–13]. A recent recent comprehensive systematic review
and meta-analysis of interventions to increase adherence to
ART found that a variety of different types of interventions
(e.g. interventions delivered via short message service
(SMS), counselling and interventions delivered by a treat-
ment supporter) were effective but effect sizes were gener-
ally small and the review did not specify specific
intervention content or theoretical approaches that were ef-
fective [14].
In order to address this, we developed the Supporting Up-
take and Adherence to ART (SUPA) intervention. In line
with the guidance of the Medical Research Council (MRC)
[15], the intervention was informed by our preparatory re-
search in which we explored and developed relevant theory.
In our preliminary studies, ART nonadherence had multiple
causes for a given individual, both intentional and uninten-
tional [16]. We subsequently identified the salient beliefs
about medicines influencing adherence [16]. In studies across
a range of illnesses and in different cultural contexts, adher-
ence was consistently related to how patients judged their
personal necessity for treatment relative to their concerns
about potential adverse effects [17]. Studies conducted
with PLWH demonstrated the utility of this Necessity
Concerns Framework (NCF) for predicting ART up-
take and adherence [18, 19].
In addition to perceptual factors influencing adher-
ence, the National Institute for Clinical Excellence
(NICE) recommends addressing practical factors such as
limitations in capacity and resources: the Perceptions
and Practicalities Approach (PAPA) [20]. To date, few
interventions have utilised this approach. One exception
is a telephone-based medicines support intervention,
where patients receiving the intervention had fewer
doubts about necessity and fewer concerns, fewer medi-
cation problems and higher reported adherence than
standard care controls [21].
The content of the SUPA intervention has been described
in detail (King K, Horne R, Cooper V, Glendinning E, Michie
S, Chalder T, SUPA Group: The development of an interven-
tion to support uptake and adherence to antiretroviral ther-
apy in people living with HIV: the SUPA intervention,
submitted). In summary, the SUPA intervention uses a Per-
ceptions and Practicalities Approach (PAPA) to support up-
take and adherence to ART. It comprises 3 key elements
aiming to address factors related to the motivation to take
treatment, elicit and help the patient overcome barriers to
implementing the intention to take treatment and help them
establish routines leading to habit formation:
– Communicate a common-sense rationale for ART
– Elicit and address specific Necessity beliefs and
Concerns about ART
– Identify and address practical barriers to ART
uptake and adherence.
This paper describes the protocol of a study to deter-
mine the efficacy of the SUPA intervention for increasing
uptake and adherence to ART.
Primary objective
– To investigate the impact of the SUPA intervention
on adherence to ART
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Secondary objectives
– To investigate the impact of the SUPA intervention
on treatment outcomes, engagement with care and
patient-reported outcomes
– To assess how patients’ beliefs about ART change
over time and how this may predict adherence and
engagement in care
– To assess the costs and cost effectiveness of
providing the intervention in the short and long-
term.
Methods
Study design
This study comprises 2 phases (Fig. 1). Phase 1 is an
observational cohort study, in which PLWH who are
ART naïve and recommended to take ART by their
clinician complete a questionnaire assessing their beliefs
about ART over a period of 12 months. Phase 2 is a
randomised controlled trial (RCT) nested within the
observational cohort study to investigate the effective-
ness of the SUPA intervention on adherence to ART and
to explore the intervention mechanism. PLWH who are
at risk of nonadherence will be recruited and ran-
domised 1:1 to the intervention and control arms. All
participants will receive usual care which is provided to
all NHS patients through clinical support from a multi-
disciplinary healthcare team including the patient’s
assigned HIV physician, nurses, pharmacists and other
healthcare professionals, such as clinical psychologists,
as required. In addition, participants in the intervention
arm will receive the SUPA intervention.
Setting
This study will be conducted in HIV clinics in National
Health Service (NHS) hospitals across England: Kings
College Hospital, Homerton University Hospital, Queen
Elizabeth hospital (Woolwich), University Hospital
Lewisham, North Middlesex University Hospital, St.
George’s Hospital, University Hospitals Birmingham
and Bradford Teaching Hospitals. The sites were se-
lected on the basis of clinician-reported issues with
suboptimal appointment attendance post HIV diagnosis.
Participants
Inclusion and exclusion criteria
Participant inclusion criteria (Phases 1 and 2): (1)
patients aged 18 years or above; (2) diagnosed HIV infec-
tion; (3) no previous prescription of ART (except women
who have previously been prescribed ART for prevention
of transmission during pregnancy and subsequently
discontinued, who are considered eligible); (4) clinical
recommendation to initiate ART treatment according to
contemporaneous British HIV Association (BHIVA)
guidelines or as deemed appropriate by the patient’s
clinician; (5) able to provide written informed consent
and available for long-term follow-up. Participant exclu-
sion criteria: (1) patients who do not speak English; (2)
those who plan to leave the country in the next 12
months and hence will not be available for follow-up
appointments or telephone follow-ups; (3) participants
already enrolled in a trial or in any research study which
encourages adherence (e.g. clinical trial of an investi-
gational medical product); (4) lack of capacity to provide
informed consent; (5) hospitalisation for a mental dis-
order in the past 2 years; (6) current suicidality or
self-harm; (7) pervasive developmental disorder; (8)
active substance misuse/dependence in last 3 months
which in the opinion of the physician or investigator
renders the patient unable to adhere to the study proto-
col; (9) patients who have previously started antiretro-
viral therapy and subsequently discontinued, except if
they have previously taken ART for pregnancy; (10)
psychiatric or addictive disorders which in the opinion
of the clinician or investigator could preclude obtaining
informed consent.
Recruitment
A two-stage enrolment process will be employed:
Patients who meet the inclusion criteria will be informed
about the study by their HIV doctor, and will subse-
quently be referred to the study team. All patients who
meet the inclusion criteria will be invited to partici-
pate in the observational component of the study
(Phase 1). Following informed consent, all participants will
complete the Beliefs about Medicines Questionnaire-ART
specific version (BMQ-ART). The clinician or Research
Assistant (RA) will score the questionnaire immedi-
ately. If the score indicates that the participant is at
high risk for nonadherence (ART-Necessity score ≤ 3
and/or ART-Concerns score ≥ 3), they will be provided
with information by the study team and invited to
consider taking part in Phase 2, the interventional
trial component. Further written informed consent to
take part in Phase 2 will be received after the patient
has been given an opportunity to consider their
participation in the study and discuss this with others
if they wish.
Confidentiality
The study will conform to the Caldicott Principles
and ethical and legal guidelines covering consent,
confidentiality and storage of data. All data will be
kept confidential in accordance with the Data Pro-
tection Act. All participants will be allocated a
study identification number, so the participants will
only be identifiable to study staff. De-identified data
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(no name, date of birth) will be stored in a
password-protected database at the UCL School of
Pharmacy for 15 years. After that time the study
register, Case Report Forms (CRFs), and consent
forms will be destroyed making it impossible to link
participants’ names to identification numbers. The
original copy of the consent form will be stored in
the patient’s case notes and a copy of the consent
form will be kept in the site file.
Randomisation
If the participant consents to participate in Phase 2,
they will be randomly allocated to one of the two
trial arms (open randomisation; ratio 1:1) by the
King’s Clinical Trials Unit (KCTU), King’s College
London. The randomisation procedure will be a
stratified block randomisation. Centres will be
blocked to ensure that there are equal participants
in each arm at each site. The randomisation sched-
ule will be incorporated into a dedicated electronic
database and kept securely within this electronic
system, inaccessible to the enrolment location. Once
an eligible participant has given written informed
consent and completed the baseline assessment, the
RA will log on to the randomisation system, enter
the participant identification number and hospital,
and will click on the ‘randomise’ function. The
treatment allocation will appear immediately on
screen and be communicated to the patient. The
confirmation of treatment allocation details will be
sent to the research team immediately. The RA will
inform the participant’s HIV clinical team on the
same day. Movement from the observational cohort
Fig. 1 Adapted CONSORT diagram of the study
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to the intervention trial or declining participation in
the trial will be recorded on the central database.
Control: care as usual (CAU)
All participants (intervention and control group) will re-
ceive care as usual. Although this may vary slightly by
clinic, this follows the same framework across all sites.
– If the participant is starting ART, standard of care
typically includes:
– Discussion with a doctor about starting ART
(including why, what is involved and the
importance of adherence);
– Consultation with a pharmacist at first
prescription discussing the importance of
adherence and potential side effects;
– Collection of 2–4 weeks of medication and
appointment with clinic nurse for safety bloods at
2–4 weeks;
– Review with their HIV doctor at 1 month;
– Routine clinic visits at 3 or 6 monthly intervals
with a nurse and HIV doctor.
– If the participant is not starting ART:
– 3 monthly consultation with HIV doctor,
discussing readiness and beliefs about medication
with a view to commencing ART;
– 3 monthly monitoring bloods with nurse.
Intervention: SUPA intervention + care as usual (CAU)
The SUPA intervention has been described in detail
in a separate publication (King K, Horne, R,
Cooper, V, Glendinning E, Michie S, Chalder T:
SUPA Group. The development of an intervention
to support uptake and adherence to antiretroviral
therapy in people living with HIV: the SUPA inter-
vention, submitted). Patients randomised to the
intervention group will receive treatment initiation
support within 1 month of enrolment into the
intervention trial. This support will be in the form
of 4 tailored treatment support sessions delivered by
a Research Nurse (RN) utilising a collaborative Cogni-
tive Behavioural Therapy (CBT) and Motivational
Interviewing (MI) approach. The sessions will be con-
ducted face-to-face (or by telephone if the patient
prefers or cannot meet face to face) and will communi-
cate a rationale for the personal necessity of medication,
elicit and address concerns about medication and
problem-solve potential practical barriers to adherence.
Sessions will be tailored to individual needs and prefer-
ences, based on (1) the individual patient’s perceptions
and practical barriers to ART identified using the
BMQ-ART, and (2) salient issues arising during the ses-
sions. An animation series and intervention manual have
been developed as tools to communicate a rationale for
the personal necessity of ART and to illustrate concerns
and potential solutions. The specific timing of the ses-
sions will differ according to the patient’s specific
needs and availability; however, the first two sessions
will take place within 1 month of enrolment, and ses-
sions 3 and 4 will provide additional support 3 and 6
months post randomisation. These appointments will
be scheduled at the patient’s convenience.
Assessment of intervention fidelity
If the patient consents to audio recording, the inter-
vention sessions will be recorded on a dictaphone. As
in previous intervention trials [22], a scale will be de-
veloped to rate the recorded sessions according to a
rating protocol. Two trained raters working independ-
ently will score randomly selected intervention re-
cordings (1 intervention session from 20% of
participants). Differences in ratings will be identified,
discussed and resolved through a process of consen-
sus and conciliation.
Participants who delay starting ART (both arms)
If participants delay or decline ART when treatment
is offered by their clinician, they will continue in the
study. For the intervention group, sessions will focus
on barriers to starting treatment, rather than ongoing
support with adherence.
Participant follow-up
Phase 1 - observational cohort study
At baseline and at the participant’s routine clinic visits 3,
6, and 12months post-baseline, the participant will
complete the observational study questionnaires (Add-
itional file 1). If the participant does not have 3-monthly
appointments as standard care, or are not attending clin-
ical appointments, they will be asked to either schedule a
research visit or complete the questionnaires over the
phone with a member of the research team.
Phase 2 – randomised controlled trial
For trial participants, the baseline visit includes enrol-
ment, randomisation and completion of the trial study
questionnaires (Additional file 2). For intervention
participants, this includes their first intervention ses-
sion. Participants in the intervention arm will then be
invited to attend additional study visits at 1, 3, 6 and
12-months post-randomisation. Participants in the
control arm will be invited to attend additional study
visits at 3, 6 and 12 months post-randomisation (Fig.
1). Expenses for study visits will bereimbursed (£10
per visit).
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Data collection
Medication event monitoring system (MEMS)
When a participant chooses to initiate treatment, the
pharmacy in each site will dispense the participant’s pre-
scription in bottles approved by the SUPA study for use
with a Medication Event Monitoring System (MEMS)
TrackCap. Site pharmacists will receive training by a
designated RA in the use of MEMS caps, and how to ex-
plain the use of MEMS cap to participants. The RA will
also explain to the participant how to use the MEMS
bottle and cap. If the first dispensing of ART in a MEMS
bottle does not coincide with a research visit, the RA
will contact the participant via telephone to give any ne-
cessary further explanation on how to use the MEMS
cap. Participants will be offered an instruction sheet
which will be given at their research visit. All pharmacy
refill data available for each participant from starting
treatment up to an including their most recent clinic
visit will be collected electronically.
Self-report measures will be completed by the partici-
pant with the help of the RA (if desired) at each study
visit. All medical data will be collected by the RA from
available patient notes and lab results. Baseline data will
be collected at the enrolment visit. Measures completed at
each assessment are shown in Additional files 1 and 2.
Primary endpoint
The proportion of months under follow-up where
adherence is greater than or equal to 90%
Adherence is defined by MEMS data. As the distribution
of this variable is unknown, we will categorise the pro-
portion of participants achieving ≥90% adherence as < vs
≥0.8 of the follow-up months. Essentially, this study as-
sesses whether the participant has been ≥90% adherent
for at least 80% of their time spent in the trial. The 80%
threshold to define a good outcome is based on the fact
that 4–6 weeks delay to ART initiation following a treat-
ment recommendation is reasonable, and if followed by
consistent ≥90% adherence to ART for the remainder of
the trial (10 of the 12 months), the participant is likely to
achieve and maintain viral load suppression. To calculate
each monthly adherence value, the percentage of adher-
ence (according to MEMS) for each individual over each
month of follow-up from randomisation will be calcu-
lated, treating every day off ART or not taking all pre-
scribed ART doses (indicating either nonadherence or
delayed treatment initiation) as 0% adherence.
Secondary endpoints
Clinical endpoints
Treatment failure Treatment failure is defined as either
failure to take up treatment or experiencing virological
failure once taking treatment, namely:
– Not starting treatment within 6 months of the
treatment recommendation.
– Not obtaining a viral load of < 50 copies/ml 6
months after commencing ART, or following viral
suppression to < 50 copies/ml a viral load rebound
to > 400 copies/ml on one occasion (single values > 50
copies/ml will be used rather than requiring
confirmation because the number of viral load
measurements during the 1 year follow-up are too
few for confirmation to be possible).
– Following viral suppression to < 50 copies/ml, 2
consecutive viral loads > 50 copies/ml.
Disengagement from care at 12months Disengage-
ment is defined as missing one or more routinely sched-
uled visits, including visits either not attended and not
rescheduled or rescheduled but not attended before the
participant’s next routine appointment is due.
Rate of ART regimen switches through 12months
The total number of drug changes is calculated over the
12-month study period, including changing from one
drug to another drug for any reason (excluding changes
from 3TC to FTC and vice versa where these are simply
due to changing a fixed dose combination tablet).
Referral out of the intervention at 12months This is
defined as being referred out of the intervention for
more specialist or intensive care (e.g. seeing a Psy-
chiatrist or Clinical Psychologist for adherence issues).
This information will be recorded in clinic notes and
monitored by the research team.
Patient-reported endpoints
Changes in perceptions of ART between baseline and
12months Perceptions of ART will be measured using
the BMQ-ART [16, 18] which was adapted following
preparatory work with the target populations [23] to
include items on culturally-specific and practical barriers
specific to ART. The BMQ-ART includes 2 scales: the
ART-Necessity scale and the ART-Concerns scale. The
ART-Necessity scale consists of 10 items which assess
how patients perceive their personal need for ART for
keeping their HIV under control, maintaining their
health and preventing illness. The ART-Concerns scale
consists of 10 items measuring concerns about potential
adverse effects of ART that have been identified in pre-
vious studies. These include fears about short- and
long-term side effects, concerns about the timing of
tablets and the disruptive effects of the ART regimen on
daily life. Participants are asked to rate the extent to
which they agree with each item on a scale with possible
responses ranging from strongly agree (scored 5) to
Horne et al. BMC Public Health          (2019) 19:905 Page 6 of 15
strongly disagree (scored 1). A total score for each scale
is computed by adding the scores for each scale item
together and dividing by the number of items. This
yields a mean score ranging from 1 to 5 for the necessity
and concerns scales.
Depression and anxiety at 12 months The Hospital
Anxiety and Depression Scale (HADS) [24] will be used to
measure anxiety and depression. This 14-item measure
was designed to detect the presence and severity of anx-
iety and depression among patients attending outpatient
clinics without the possibility that scores would be con-
taminated by reporting of physical symptoms. Possible
responses for each item ranged from 0 to 3, with each
seven-item scale having a total possible score range of 0 to
21. Higher scores indicate greater anxiety or depression.
Good psychometric properties of the HADS have been
found in studies including medical outpatients [24, 25].
Health-related quality of life at 12months The
Euroqol-5D (EQ-5D-5 L) is a self-completed measure of
health-related quality of life (HRQoL), comprising 5
questions relating to dimensions of health: mobility,
self-care, ability to undertake usual activities, pain/dis-
comfort, and anxiety/depression [26]. Each dimension
has 5 levels from ‘no problems’ (scored 1) to ‘extreme
problems’ (scored 5). This results in a score on each
dimension that can be combined to a 5-digit number
describing the patient’s state of health. These health states
will be combined with population weights to estimate in-
dividual utility scores ranging from 0 (worst health) to 1
(full health), required for generating quality-adjusted life
years [27, 28]. The scale also includes a visual analogue
scale (EQ-VAS) where the participant is required to indi-
cate their level of health on a vertical scale with endpoints
labelled ‘the best health you can imagine’ and ‘the worst
health you can imagine’. This score (from 0 to 100) re-
presents the patient’s judgement of their own health.
Health and social service use at 12months Health
and social service utilisation will be collected at baseline
and each follow-up using a modified version of the
Client Service Receipt Inventory (CSRI) [29]. The CSRI is
a widely used measure that can be adapted to meet the
needs of each study/context in which it is used. It captures
retrospective data on accommodation, employment (and
time off work), contacts with community health profes-
sionals (e.g. GPs, social workers), hospital care (emergency
department, inpatient and outpatient), laboratory tests,
medication (including ART), social care and informal care
from family and friends (i.e. support without payment).
The CSRI enquires about whether contacts had occurred,
how many, and where appropriate, the duration.
Symptoms attributed to having HIV and/or taking
ART Each participant’s experience of symptoms will be
measured using the Symptoms Associated with HIV and
ART Questionnaire (SAQ) [30]. The SAQ measure con-
sists of 16 symptoms and a section where the participant
is invited to add any symptoms that they are experiencing
that are not listed. The participant answers by saying
whether they experience each symptom or not (yes/no).
Where the answer is ‘yes,’ the participant is asked to evalu-
ate the severity of the symptom on a 5-point Likert-type
scale with responses ranging from ‘very mild’ to ‘very
severe.’ In addition, participants are asked to indicate
whether they think the symptom is being caused by HIV,
ART, both HIV and ART or neither. Scores will be ge-
nerated for the total number of symptoms the partici-
pant is experiencing (possible range 0–16), the
number of symptoms that the participant attributes to
HIV (possible range 0–16), and the number of symp-
toms that the participant attributes to ART side effects
(possible range 0–16).
Illness perceptions The 9-item Brief Illness Perception
Questionnaire (bIPQ) [31] will be used to assess parti-
cipants’ cognitive and emotional illness perceptions.
Participants are presented with statements about HIV
such as ‘how much does your illness affect your life?’.
Eight items measure participants’ perceptions of the
timeline, consequences, controllability, emotional effects
and understanding of their HIV on a scale of 0–10 with
anchors relevant to each dimension, where higher scores
indicate a greater strength of belief in the particular
dimension. The final item asks participants to specify the
3 most important factors that they believe caused their
condition. A total score will be calculated by reverse
scoring 3 items and adding them to the total score of
the remaining 5 items. A higher score reflects a more
threatening view of the illness.
Self-reported adherence Adherence to ART is mea-
sured using the Medication Adherence Report Scale-5
item version, (MARS-5) [32] consisting of 5 statements
about different ways in which the participant might take
their medication e.g. ‘I forget to take my medicines,’
scored on a 5-point Likert-type scale, where 1 = always
and 5 = never. The statements are introduced in a
non-threatening manner in order to minimise social
pressure to under-report nonadherence. Adherence is
expressed as a continuous scale with possible scores
ranging from 5 to 25 with higher scores indicating
greater adherence.
ART intrusiveness The ART Intrusiveness Scale [33]
consists of 10 questions which assesses the frequency
and magnitude that the participants’ medication
Horne et al. BMC Public Health          (2019) 19:905 Page 7 of 15
interferes with different aspects of their lives. This meas-
ure consists of 10 statements about ways in which the
medication intrudes in their life, e.g. ‘My ART restricts
my ability to travel’, scored for frequency on a 5-point
Likert-type scale, where 1 = never and 5 = always, and
magnitude of the intrusion also on a 5-point Likert-type
scale, where 1 = low interference and 5 = high inter-
ference. The items are summed for both frequency and
magnitude of intrusion and higher scores indicate
greater intrusion.
Readiness to initiate ART HIV Treatment Readiness
Scale. Following a treatment offer, patients’ perceived
readiness to initiate ART will be measured using a single
item developed for this study “I feel ready to start
antiretroviral medication”. The participant is asked to
indicate the extent to which they agree or disagree
with this statement on a 5-point Likert-type scale
with response anchors “not ready” and “very ready.”
This item was created based on the ‘readiness ruler’
[34], a motivational interviewing technique used
within the SUPA intervention.
Knowledge about HIV treatment Patients’ knowledge
about HIV treatment will be measured using 13 items
from the HIV Treatment Knowledge Scale [35]. The
original scale consists of 21 items assessing know-
ledge about HIV and its treatment, e.g. “HIV medica-
tions help the body’s immune system get stronger
(CD4 increase)”. Eight items were removed either be-
cause they assessed knowledge about transmission ra-
ther than treatment, or because the topic had been
measured in other study questionnaires. Participants
are required to indicate whether they believe each
statement is true or false or whether they do not
know the answer. A total score is calculated by sum-
ming the number of correct responses and dividing
by the total number of scale items. This yields a per-
centage of correct responses, with higher scores indi-
cating greater HIV treatment knowledge.
Qualitative data
A subset of at least 20 participants receiving the SUPA
intervention will be interviewed by a RA within 3
months of receiving the last intervention session. To
avoid bias, the RA will be independent to the RN deliv-
ering the intervention. The interview schedule will ex-
plore participants’ perceptions of the intervention (e.g.
overall impression, positive features, room for improve-
ment, ease of comprehension, perceived effect on adher-
ence and overall wellbeing). Transcripts will be
subjected to thematic analysis.
Sample size calculations
Phase 1 - observational cohort
Our risk assessment for nonadherence was based on the
findings of a previous prospective study of beliefs and
adherence among PLWH [19]. Phase 1 assesses whether
the initial risk assessment is valid in the current sample.
As such we will not aim to obtain a particular sample
size, but rather recruit as many patients as possible (all
eligible patients attending the clinic will be invited to
Phase 1).
Phase 2 – trial
Since this study uses a novel measure combining both
uptake and adherence, there are no data to inform a
sample size calculation. It is plausible that the distribu-
tion could be bimodal or highly skewed. As the propor-
tion with ≥90% adherence will also be bounded by [0,1],
standard sample size calculations based on the normal
distribution would likely be inappropriate, even if a
standard deviation could be hypothesised. This study
therefore defines a good primary outcome as ≥80% of
follow-up months with ≥90% adherence. Since the study
selects for an at-risk group, we would expect a large dif-
ference between control and intervention groups, and a
15% difference between groups is considered clinically
significant based on estimated intervention costs. Table 1
shows the number of participants needed in each arm to
detect a 15% difference in adherence from a range of pos-
sible control group percentages with > = 0.8 of follow-up
months with ≥90% adherence (80% power, 2-sided
alpha = 0.05). We will therefore recruit 372 participants.
Statistical methods and analysis
The SUPA intervention is hypothesised to be superior to
care as usual, and therefore the planned analysis is
intention to treat, including all randomised participants,
with all participants analysed according to the study
group to which they were randomised regardless of sub-
sequent treatment received. Primary analysis will include
all randomised participants other than those randomised
in error (defined as not intending to randomise the
participant through e.g. miscommunication, rather than
Table 1 Sample size calculations for Phase 2 – trial
Standard of care group % with
> 0.8 of follow-up months with
≥90% adherence
Intervention group %
with > 0.8 of follow-up
months with ≥90%
adherence
N
per
arm
Total
N
35% 50% 183 366
45% 60% 186 372
50% 65% 183 366
60% 75% 165 330
70% 85% 134 268
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a participant or clinician decision once the allocation
has been given).
A per-protocol analysis will be carried out on the
primary endpoint including all participants in the inter-
vention group who attended all 4 (2 + 1 + 1) sessions. If
the intention to treat and per-protocol analyses on the
primary endpoint leads to inconsistent results, then
per-protocol analysis will also be carried out on all the
other endpoints.
Continuous variables will be summarised by medians
and IQRs or means and standard deviations as appro-
priate depending on the distribution, and compared be-
tween groups using ranksum tests or t-tests respectively.
Comparisons of change from baseline in continuous
variables will adjust for any baseline imbalances using
either quantile or normal linear regression (depending
on the shape of the distribution).
Categorical variables will be summarised by frequency
tables, and compared between groups using chi-squared
tests, unless any cell count is < 5 or cell percentage is
< 5% in which case exact tests will be used. Binary
variables will be summarised by percentages, using
standard exact 95% CI for the risk differences.
Time-to-event variables will be summarised using
Kaplan-Meier curves and average differences between
randomised groups estimated using Cox models. Patients
without the event recorded will be censored at their last
clinic visit. Proportionality of hazards will be tested; where
significant departures exist, varying differences between
randomised groups over time will be estimated using
flexible parametric models of Royston and Parmar. Rate of
treatment switching will be analysed using Poisson re-
gression, including all changes to ART as events and
the total time under follow-up through the earliest of
12 months or the last patient visit as the person-time
at risk. Primary analysis will not stratify by clinical centre.
Subgroup analyses
Subgroup analyses will be performed to assess hetero-
geneity in differences between randomised groups for the
primary endpoint according to gender, ethnicity, number
of intervention sessions attended, early (treatment indi-
cated at point of diagnosis) vs late diagnosis (treatment
not indicated at point of diagnosis), starting for clinical
need vs starting for treatment as prevention, baseline CD4
count, and baseline BMQ scores - low Necessity vs high
Concerns vs both low Necessity and high Concerns. Sub-
group analyses will use logistic regression to model inter-
actions between randomised group and the factors above.
Health economic analyses
Perspective
The evaluation will primarily adopt a health and social
care perspective as preferred by the National Institute
for Health and Care Excellence (NICE) for decision-
making, including both direct and indirect costs of low
uptake and sub-optimal adherence. Other resources
relevant to a wider societal perspective such as informal
care and productivity loss (due to time off work) will be
included in the secondary analyses.
Intervention costs will be estimated from information
relating to staff time (RNs) in delivering the SUPA inter-
vention, including time spent training and actually deliv-
ering the intervention, and other non-staff costs (e.g.
manual development and printing). The frequency and
duration of health and social care service use data will
be combined with appropriate unit costs to generate
total care costs per patient.
Costs will be compared between intervention and
control groups. Bootstrapping methods will be used to
produce confidence intervals around the cost differences
to account for skewness often associated with the distri-
bution of cost data. Costs will be combined with the
primary trial outcome in the form of cost-effectiveness
analyses. However, as the primary outcome is not a clin-
ical outcome and is condition specific, quality adjusted
life-years (QALYs) estimated from the EQ-5D will be
used to estimate cost-effectiveness. The use of QALYs
and the EQ-5D in HIV is supported by previous work. If
the intervention results in reduced costs and better
outcomes then it will be defined as being ‘dominant.’
However, supposing the costs are higher and outcomes
are better, then incremental cost-effectiveness ratios will
be calculated to show the extra costs incurred to gain an
extra level of outcome. Uncertainty around cost-effect-
iveness estimates will be explored using cost-effective-
ness planes. The results will be further evaluated using
cost-effectiveness acceptability curves.
Determining the cost effectiveness of the long-term impact
of the interventions
Although we will measure costs, QALYs and the cost
per QALY over the study period, this information will be
limited because it would be expected that QALY gains
would largely occur later in time. To address this issue a
Markov model will be constructed to examine how
patients might move from one health state to another
over a longer period of time. Health states will be
defined according to CD4 counts or viral load. The
probabilities of moving from one health state to another
will be based on a review of the literature and from
expert opinion. Assuming some degree of patient
variation, the data collected in the trial will give infor-
mation on EQ-5D utility scores and costs that are asso-
ciated with different CD4 ranges and where necessary
this information will be supplemented by data from the
literature. As well as allowing us to assess the long-term
cost-effectiveness of the interventions, this approach will
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enable an estimation of the long-term cost associated
with different levels of ART uptake and adherence. This
will be of importance from a public health perspective in
that it will illustrate the economic savings that might be
made through interventions. Increased uptake and
adherence may have further benefits if infections in
others are reduced and we will explore the possibility of
incorporating such externalities into the model. The
time horizon used will depend on data availability, but is
it expected that we will measure costs and outcomes
over a 5–10, and 15-year period. The results over the
longer periods will by definition be more speculative.
Internal feasibility review
Baseline data from the first 40 randomised patients (and
1-month data for those randomised to the intervention
arm) will be reviewed with the Programme Management
Group (PMG) and Programme Steering Committee
(PSC) at respective group meetings. The groups will
assess:
1. Feasibility of recruitment and retention, identifying
barriers to recruitment/retention and problems in
delivery.
2. Acceptability of study measures (Control and
Intervention arms).
3. Acceptability of the intervention by patients
(Intervention arm only).
4. Capacity of trial and local site personnel, including
capacity of clinics to accommodate research staff,
determining whether trial centres are fulfilling their
commitments (i.e. helping with the identification
and introduction of patients), and determining
where further staff is needed to recruit patients
and/or to deliver the intervention.
The findings of the feasibility review, along with par-
ticipant feedback, will be used to make any necessary
modifications to the conduct of the trial.
Adverse events
Adverse events (AE) include any clinical change, disease
or disorder experienced by the participant during their
participation in the trial, whether or not considered
related to participation in the trial. A Serious Adverse
Event (SAE) will be defined according to usual clinical
trial definitions. If the RA/RN is uncertain about
whether the AE is an SAE, they will contact the centre
Principal Investigator for their opinion. All SAEs must
be reported by the RA/RN to the patient’s doctor (or
doctor to the RA/RN), the centre Principal Investigator
and the Trial Manager immediately. SAEs that are re-
lated to administration of any of the research procedures
will be reported to the Sponsor and also sent to REC by
the CI (or delegated individual) within 15 days of the CI
becoming aware of the event.
After an SAE, a decision will be made as to whether
the participant should be withdrawn from the trial, or
need an alteration in their standard care. Arrangements
will be made by the RN for further assessment and
management as necessary. One month after an SAE, the
RA/RN will provide both the site Principal Investigator
and Trial Manager with a follow-up report. If the SAE is
not resolved, further monthly reports will be sent via the
Trial Manager to the Independent Data Monitoring
Committee (IDMC). The RA/RN will forward these
reports to the Research Ethics Committee, Sponsor, and
local Research and Development (R&D) office.
Trial discontinuation
If a member of the clinical care team or the RN feels that
the intervention is detrimental (for example, causing
distress), the patient can be referred out of the interven-
tion. Referral to a more specialised professional should be
carried out by the patient’s Clinician. Participants may dis-
continue from participation at any time, at the discretion
of the Investigator. Specific reasons for discontinuing a
participant from either study are:
1. Withdrawal of informed consent.
2. Development of exclusion criteria or other safety
reasons during the study.
3. Incorrect enrolment or randomisation of the
participant.
Participation in other studies
Participation in other studies may be permitted (for
example, qualitative or questionnaire-based studies) with
the prior consent of the PMG. Patients who are participat-
ing in a study which encourages adherence (i.e. clinical
trial of an investigational medical product) will be
excluded.
Strategies to promote recruitment
The following steps will be taken in order to achieve
adequate participant enrolment
1. An RA will attend multidisciplinary clinical
meetings at each site in order to identify study
eligible patients.
2. Where possible an RA will be present at HIV clinics
when ART-naïve patients have pre-booked
appointments with a consultant and spoke with the
consultant prior to the appointment in order to
remind them of the patient’s eligibility for the
trial. The RA will also attend emergency clinics
in order to recruit patients attending clinics who
are not on ART.
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3. Written information has been developed to inform
patients about different types of research (e.g.
observational studies and randomised controlled
trials). This is intended to help patients to make an
informed decision about whether to take part in
each part of the study.
Strategies to promote data completeness
We will take the following steps in order to promote
participant retention and complete follow-up:
1. Attempt to make the research visit convenient for
participants by booking research visits to
correspond with their regular care visits.
2. Participants will be contacted by their preferred
mode of contact ahead of their research
appointments to remind them and confirm
attendance.
3. Participants will be offered the option of completing
follow-up questionnaires by telephone.
4. Contact details will be checked at each
appointment.
5. We will keep in touch with participants by sending
a birthday card or text (provided the participant has
consented to receive communication from us).
If the participant is withdrawn at the request of the
Researcher or Clinician, final follow-up data should be
collected as soon as possible (if appropriate). If the
participant wishes to fully withdraw from Phase 1 or 2,
the RA will contact the participant to ascertain the
reason for withdrawal (although the patient does not
have to give any reason), and ask whether they consent
for previously collected data to be kept and analysed.
The RA/RN will ensure that every effort is made to
obtain any final follow up data (including MEMS caps).
If the patient chooses to withdraw from attending the
intervention only (not the trial), the RA should attempt
to request permission to complete the further research
follow-up visits (including keeping the MEMS caps) at
the scheduled time points.
Trial organisation and management
This study is being organised by the UCL School of
Pharmacy, and sponsored by Brighton and Sussex
University Hospitals NHS Trust. It is funded and has
been peer-reviewed by the National Institute for Health
Research (NIHR). Neither the sponsor nor the funding
body were or will be involved in the study design, data
collection, data analysis, interpretation of data, writing
of the manuscript or the decision to submit the manu-
script for publication.
The study has been given a favourable ethical opinion
for conduct by the East of England–Essex Research Ethics
Committee (13/EE/0235). It is overseen by the SUPA Trial
Management Group (TMG), Programme Management
Group (PMG), Independent Data Monitoring Committee
(IDMC) and Programme Steering Committee (PSC). The
trial was retrospectively registered with the ISRCTN
(35514212) on 21/02/2014. Further details on the charter
for each group can be found in Table 2.
Ethics approvals
The research will be conducted in accordance with Good
Clinical Practice and all applicable regulatory require-
ments including the Research Governance Framework
and the Medicines for Human Use (Clinical Trial) Regula-
tions 2004, 2006 and any subsequent amendments. Any
modifications to the protocol will be agreed upon by the
TMG and PMG, and approved by the REC.
Trial status
The trial opened to recruitment in February 2014 and
recruitment closed in June 2017, with both Phase 1 and 2
patients in follow up. No data cleaning or analysis of the
trial has been executed prior to submission of this
manuscript.
Auditing trial conduct
Trial data inputed into the online database will be
reviewed throughout the trial for accuracy and complete-
ness by the programme manager(s) and a reviewer who
has not been responsible for data collection. Recruitment
figures from each site will be reviewed monthly by the
programme manager(s) and supplied as a report quarterly
to the Programme Management Group and monthly to
site investigatorssite investigators. The IDMC will review
recruitment figures and data completeness annually.
Ancillary and post-trial care
Local approvals and indemnity will be sought by each
participating centre through their local R&D depart-
ment. Details of local indemnity arrangements ca1n be
obtained through each centre’s NHS R&D department.
Stopping guidelines
The IDMC will review blinded interim analyses by the
IDMC annually. If the committee feels that the arms are
unbalanced and being in one group is detrimental, the
IDMC will advise the PSC who will review the findings
and decide whether or not the trial should be stopped.
Dissemination policy
Study findings will be disseminated through publication
in peer-reviewed scientific journals, national and inter-
national conferences, HIV community publications and
the NIHR Journals library.
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Discussion
We have described the design of the Supporting Uptake
and Adherence to ART (SUPA) trial, an observational
cohort study with nested randomised controlled trial
evaluating the effectiveness of a CBT-based intervention
to increase uptake and adherence to ART by addressing
perceptual and practical barriers.
The intervention is based on the Necessity Concerns
Framework and aims to address both perceptual and
practical barriers to adherence as recommended by
NICE [20] and BHIVA guidelines [9]. The intervention
has been developed according to published guidelines
for the development of complex interventions [15] and
builds on preparatory research with PLWH showing that
Table 2 Trial organisation and management
Group Contact details
Sponsor Trial Sponsor: Brighton and Sussex
University Hospitals NHS Trust; Sponsor’s
Reference 13/117/HOR; Contact name
Scott Harfield; Address: Research &
Development Directorate, Royal Sussex
County Hospital, Eastern Road,
Brighton, BN2 5BE
Telephone: 01273 696,955 ext. 3538
E-mail: sponsorship.approvals@bsuh.nhs.uk
Main role Specific responsibilities
Trial Management Group
(TMG)
(Chief investigator,
Programme Managers)
Responsible for the design and conduct
of SUPA and day to day management
of the trial
-study planning
-organisation of committee meetings-Provide annual report to funder
-provide accrual figures to each site-Budget administration and contractual issues with
individual centres-Advice for lead site investigators-Ethics committee and R&D
applications-Data verification-Randomisation-Organisation of data storage
-preparation of protocol and revisions to trial documents,
-managing publication of study reports
-maintaining databases, randomising patients,
-ensuring complete and correct data
-preparing reports
-dealing with research governance
Programme Management
Group (PMG)
Assisting in managing the trial,
including the clinical and practical
aspects
-input into and comment on the protocol and all trial documents
-develop strategies to address any issues with recruitment
-provide clinical or other expert guidance on clinical and practical queries and interpretation
of information recorded on CRFs
-input into the meetings of the PSC and IDMC when appropriate (open sections only)
-provide responses for and consider the implications of any recommendations made by
the IDMC and accepted by the PSC
Programme Steering
Committee (PSC)
To act as the oversight body for
this trial on behalf of the
Sponsor/Funder
-provide expert oversight of the programme
-make decisions as to the future continuation (or otherwise) of the programme
-receive letters of feedback from the IDMC and consider their recommendations
-assess the impact and relevance of any accumulating external evidence
-monitor recruitment and follow-up rates and review strategies from PMG to deal with
problems
-approve any amendments to the protocol, where appropriate
-approve any proposals by the PMG concerning any change to the design of the
programme, including additional substudies
-approve / comment on the statistical analysis plan, publication policy, main programme
manuscript
-approve external or early internal requests for release of data
Independent Data
Monitoring Committee
(IDMC)
Safeguard the interests of
participants, assess the safety
and efficacy of the interventions
during the trial, and monitor
the overall conduct of the trial.
It is independent from the
Sponsor.
-receive and review information on the progress and accruing data of this programme and
provide advice on the conduct of the programme to the Programme Steering Committee
(PSC)
-inform the Chair of the PSC if, in their view the results are likely to convince a broad range
of clinicians, including those supporting the programme and the general clinical community,
that, on balance, one trial arm is clearly indicated
-perform interim review of the programme’s progress including updated figures on
recruitment, data quality, adherence to protocol treatment and follow-up, and main
outcomes and safety data
-monitor: evidence for treatment differences in the main efficacy outcome measures,
evidence for treatment harm, recruitment figures and losses to follow-up, compliance with
the protocol, sample size assumptions, compliance with previous IDMC recommendations,
data quality and completeness
-assess the impact and relevance of external evidence
-suggest additional data analyses if necessary
-advise on protocol modifications proposed by investigators
Lead Site Investigators Responsible for local site trial
management
In each participating centre a lead investigator (HIV consultant) will be identified, to be
responsible for identification of patients, recruitment, data collection and completion of
CRFs, along with follow up of study patients and adherence to study protocol at their local site.
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uptake and adherence to ART is driven by patients’ per-
ceptions of their personal necessity for ART and con-
cerns about adverse effects [18, 19]. To our knowledge,
this is the first study to provide support at the time of a
treatment recommendation to PLWH who may be at
risk of delaying uptake or developing issues with adher-
ence. This study targets individuals who may be consid-
ered as being hard to reach, and who are not usually
represented in randomised trials. The study design al-
lows the examination of process variables and the mech-
anism by which the intervention exerts its effect. The cost
effectiveness analysis will enable health-care service pro-
viders to make informed decisions about the value of the
intervention.
While it was not possible to mask the allocation of
participants to intervention or control groups, we
have taken steps to reduce bias, including blinding of
the statistical team to group allocation and ensuring
that data is not collected or entered by those deliver-
ing the intervention. It possible that the primary out-
come measure (MEMS) may impact on adherence as
it serves as a reminder to participants that they are
monitored. However, the impact of adherence moni-
toring alone is likely to be minimal [36]. Although
participants are selected for risk of delay to initiate
treatment and nonadherence using a screening tool
(BMQ-ART), patients who decline to take part in the
study may represent a different group who are more
at risk of disengaging from care. However, these
participants will be followed up in the observational
cohort, therefore their virological outcomes can be
compared with those of trial participants.
This is the first study to apply the perceptions and
practicalities approach recommended by NICE [20] to
the design of an intervention to increase uptake and
adherence to ART. It will provide information on the
efficacy of the intervention as well as the mechanism by
which the intervention exerts its effect. The findings
will enable patients, healthcare providers and policy
makers to make informed decisions about the value
of the intervention.
Additional files
Additional file 1: Summary of data collection at each timepoint (Phase
1 – observational study). (DOCX 14 kb)
Additional file 2: Summary of data collection at each timepoint (Phase
2 – trial). (DOCX 41 kb)
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